company background image
A290650 logo

L&C BIOLTD KOSDAQ:A290650 Stock Report

Last Price

₩19.00k

Market Cap

₩431.0b

7D

1.2%

1Y

-43.6%

Updated

21 Aug, 2024

Data

Company Financials

A290650 Stock Overview

L&C Bio Co., Ltd operates as a research and development company in tissue regeneration medicine.

A290650 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance5/6
Financial Health3/6
Dividends0/6

L&C BIO Co.,LTD Competitors

Price History & Performance

Summary of all time highs, changes and price drops for L&C BIOLTD
Historical stock prices
Current Share Price₩19,000.00
52 Week High₩39,650.00
52 Week Low₩16,480.00
Beta0.36
11 Month Change-8.21%
3 Month Change-5.24%
1 Year Change-43.62%
33 Year Change-49.40%
5 Year Change181.48%
Change since IPO111.50%

Recent News & Updates

Here's Why L&C BIOLTD (KOSDAQ:290650) Has A Meaningful Debt Burden

Aug 06
Here's Why L&C BIOLTD (KOSDAQ:290650) Has A Meaningful Debt Burden

What L&C BIO Co.,LTD's (KOSDAQ:290650) 27% Share Price Gain Is Not Telling You

Jul 05
What L&C BIO Co.,LTD's (KOSDAQ:290650) 27% Share Price Gain Is Not Telling You

L&C Bio's (KOSDAQ:290650) Performance Raises Some Questions

Mar 27
L&C Bio's (KOSDAQ:290650) Performance Raises Some Questions

Recent updates

Here's Why L&C BIOLTD (KOSDAQ:290650) Has A Meaningful Debt Burden

Aug 06
Here's Why L&C BIOLTD (KOSDAQ:290650) Has A Meaningful Debt Burden

What L&C BIO Co.,LTD's (KOSDAQ:290650) 27% Share Price Gain Is Not Telling You

Jul 05
What L&C BIO Co.,LTD's (KOSDAQ:290650) 27% Share Price Gain Is Not Telling You

L&C Bio's (KOSDAQ:290650) Performance Raises Some Questions

Mar 27
L&C Bio's (KOSDAQ:290650) Performance Raises Some Questions

Does L&C Bio (KOSDAQ:290650) Deserve A Spot On Your Watchlist?

Apr 20
Does L&C Bio (KOSDAQ:290650) Deserve A Spot On Your Watchlist?

L&C Bio's (KOSDAQ:290650) Earnings Are Of Questionable Quality

Apr 01
L&C Bio's (KOSDAQ:290650) Earnings Are Of Questionable Quality

Is L&C Bio (KOSDAQ:290650) A Risky Investment?

Mar 02
Is L&C Bio (KOSDAQ:290650) A Risky Investment?

Announcing: L&C Bio (KOSDAQ:290650) Stock Increased An Energizing 163% In The Last Year

Feb 03
Announcing: L&C Bio (KOSDAQ:290650) Stock Increased An Energizing 163% In The Last Year

What Is The Ownership Structure Like For L&C Bio Co., Ltd (KOSDAQ:290650)?

Jan 04
What Is The Ownership Structure Like For L&C Bio Co., Ltd (KOSDAQ:290650)?

Should You Be Excited About L&C Bio Co., Ltd's (KOSDAQ:290650) 16% Return On Equity?

Dec 08
Should You Be Excited About L&C Bio Co., Ltd's (KOSDAQ:290650) 16% Return On Equity?

Shareholder Returns

A290650KR BiotechsKR Market
7D1.2%3.2%2.9%
1Y-43.6%37.4%4.4%

Return vs Industry: A290650 underperformed the KR Biotechs industry which returned 37.4% over the past year.

Return vs Market: A290650 underperformed the KR Market which returned 4.4% over the past year.

Price Volatility

Is A290650's price volatile compared to industry and market?
A290650 volatility
A290650 Average Weekly Movement7.4%
Biotechs Industry Average Movement9.6%
Market Average Movement6.5%
10% most volatile stocks in KR Market12.1%
10% least volatile stocks in KR Market3.4%

Stable Share Price: A290650's share price has been volatile over the past 3 months.

Volatility Over Time: A290650's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2011124Chul Lee Whanwww.lncbio.co.kr

L&C Bio Co., Ltd operates as a research and development company in tissue regeneration medicine. It offers human tissue, medical device, and cosmetics products. The company was founded in 2011 and is headquartered in Seongnam-si, South Korea.

L&C BIO Co.,LTD Fundamentals Summary

How do L&C BIOLTD's earnings and revenue compare to its market cap?
A290650 fundamental statistics
Market cap₩431.01b
Earnings (TTM)₩49.31b
Revenue (TTM)₩70.64b

8.7x

P/E Ratio

6.1x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A290650 income statement (TTM)
Revenue₩70.64b
Cost of Revenue₩35.14b
Gross Profit₩35.50b
Other Expenses-₩13.82b
Earnings₩49.31b

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)2.17k
Gross Margin50.25%
Net Profit Margin69.81%
Debt/Equity Ratio51.4%

How did A290650 perform over the long term?

See historical performance and comparison

Dividends

0.5%

Current Dividend Yield

5%

Payout Ratio